journal article·2023-12-31Open access

Novel transdermal curcumin therapeutic preserves endothelial barrier function in a high-dose LPS rat model

William H. Nugent, Danuel A. Carr, Joel Friedman, Bjorn K. Song

Abstract

Sepsis is a devastating complication of infection and injury that, through widespread endothelial dysfunction, can cause perfusion deficits and multi-organ failure. To address the recognised need for therapeutics targetting the endothelial barrier, a topical formulation (CUR; VASCEPTOR™; Vascarta Inc, Summit, NJ) was developed to transdermally deliver bio-active concentrations of curcumin—an anti-inflammatory and nitric oxide promoter. Male, Sprague Dawley rats were treated daily with lipopolysaccharide (LPS, 10 mg/kg, IP) to induce endotoxemia, and topical applications of Vehicle Control (LPS + VC; N = 7) or Curcumin (LPS + CUR; N = 7). A third group received neither LPS nor treatment (No-LPS; N = 8). After 72 h, animals were surgically prepared for measurements of physiology and endothelial dysfunction in the exteriorised spinotrapezius muscle through the extravasation of 67 kDa TRITC-BSA (albumin) and 500 kDa FITC-dextran (dextran). At 72 h, LPS + VC saw weight loss, and increases to pulse pressure, lactate, pCO2, CXCL5 (vs No-LPS) and IL-6 (vs 0 h; p < 0.05). LPS + CUR was similar to No-LPS, but with hypotension. Phenylephrine response was increased in LPS + CUR. Regarding endothelial function, LPS + CUR albumin and dextran extravasation were significantly reduced versus LPS + VC suggesting that Curcumin mitigated endotoxemic endothelial dysfunction. The speculated mechanisms are nitric oxide modulation of the endothelium and/or an indirect anti-inflammatory effect.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Pharmacological Effects of Medicinal Plants · Biochemical effects in animals

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Song Biotechnologies LLC, Cockeysville, MD, USA

Department of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY, USA

Vascarta, Inc, Summit, NJ, USA

Funding

TheFJC · VASCARTA, Inc · Song Biotechnologies, LLC

References (38)

Show source-provided references
1. 10.1016/S0140-6736(19)32989-710.1016/S0140-6736(19)32989-7 ↗
2. Ince C. · Crit Care · 2005 · 9 · S1310.1186/cc3753 ↗
3. 10.1126/scitranslmed.300201110.1126/scitranslmed.3002011 ↗
4. 10.1097/SHK.000000000000051310.1097/SHK.0000000000000513 ↗
5. 10.1371/journal.pone.008090510.1371/journal.pone.0080905 ↗
6. 10.1097/01.CCM.0000298158.12101.4110.1097/01.CCM.0000298158.12101.41 ↗
7. Park JS · J Emerg Med · 2015 · 49 · 26110.1016/j.jemermed.2015.02.038 ↗
8. 10.1007/s00068-022-01991-210.1007/s00068-022-01991-2 ↗
9. 10.1097/SHK.000000000000047310.1097/SHK.0000000000000473 ↗
10. Langston JC · Vasc Biol · 2022 · 4 · R1510.1530/VB-22-0003 ↗
11. 10.1016/j.molmed.2014.01.00710.1016/j.molmed.2014.01.007 ↗
12. 10.1097/CCM.000000000000484210.1097/CCM.0000000000004842 ↗
13. 10.1016/j.niox.2014.09.00110.1016/j.niox.2014.09.001 ↗
14. 10.1139/cjpp-2015-015610.1139/cjpp-2015-0156 ↗
15. 10.1620/tjem.253.6910.1620/tjem.253.69 ↗
16. Lukita-Atmadja W · Shock · 2002 · 17 · 39910.1097/00024382-200205000-00010 ↗
17. 10.18632/aging.10114910.18632/aging.101149 ↗
18. Coletta C · Crit Care · 2014 · 18 · 51110.1186/s13054-014-0511-3 ↗
19. Gundersen Y · Intensive Care Med · 1998 · 24 · 125710.1007/s001340050759 ↗
20. Tian R · Nitric Oxide · 2020 · 96 · 5410.1016/j.niox.2020.01.007 ↗
21. 10.1016/j.freeradbiomed.2020.09.02510.1016/j.freeradbiomed.2020.09.025 ↗
22. 10.1016/j.niox.2019.04.01110.1016/j.niox.2019.04.011 ↗
23. 10.1016/j.lfs.2006.06.04810.1016/j.lfs.2006.06.048 ↗
24. 10.1021/acs.jmedchem.6b0097510.1021/acs.jmedchem.6b00975 ↗
25. 10.1016/j.canlet.2008.03.02510.1016/j.canlet.2008.03.025 ↗
26. 10.3390/ijms2118661910.3390/ijms21186619 ↗
27. 10.1016/0026-2862(73)90055-110.1016/0026-2862(73)90055-1 ↗
28. 10.1016/S0026-2862(03)00061-X10.1016/S0026-2862(03)00061-X ↗
29. 10.1016/j.mvr.2015.12.00710.1016/j.mvr.2015.12.007 ↗
30. 10.1016/j.mvr.2014.07.00510.1016/j.mvr.2014.07.005 ↗
31. 10.1080/21691401.2021.201325110.1080/21691401.2021.2013251 ↗
32. Nugent WH · Shock · 2017 · 52 · 108
33. 10.1080/21691401.2020.180944110.1080/21691401.2020.1809441 ↗
34. 10.2174/15701610778202338910.2174/157016107782023389 ↗
35. Czyzynska-Cichon I · Int J Nanomedicine · 2021 · 16 · 137710.2147/IJN.S291945 ↗
36. Renkin EM · J Appl Physiol · 1989 · 66 · 205610.1152/jappl.1989.66.5.2056 ↗
37. 10.1073/pnas.200764211710.1073/pnas.2007642117 ↗
38. Hall E · Regul Pept · 2005 · 131 · 3410.1016/j.regpep.2005.06.006 ↗